Related Articles
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer